NurExone Biologic ( (TSE:NRX) ) just unveiled an update.
NurExone Biologic Inc. presented promising preclinical data on its ExoPTEN therapy for optic nerve regeneration at the ARVO 2025 conference, showcasing its potential to restore retinal activity and improve optic nerve structure in a rat model. This development is part of NurExone’s broader ExoTherapy™ platform, which also targets spinal cord and facial nerve regeneration, and highlights the company’s innovative approach in regenerative medicine. The presentation generated significant interest, indicating a growing recognition of exosome-based therapies as a potential new frontier in treating central nervous system injuries.
More about NurExone Biologic
NurExone Biologic Inc. is a biotechnology company listed on the TSX Venture Exchange, OTCQB, and Frankfurt, focusing on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has shown promising preclinical data for treating acute spinal cord and optic nerve injuries, targeting multi-billion-dollar markets. The company is also working on obtaining regulatory milestones to advance towards clinical trials in the U.S. and Europe, and has established a U.S. subsidiary to support its North American growth strategy.
Average Trading Volume: 29,325
Technical Sentiment Signal: Buy
Current Market Cap: C$38.58M
For an in-depth examination of NRX stock, go to TipRanks’ Stock Analysis page.